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A B S T R A C T
Background: Chronic respiratory disease causes substantial global morbidity and mortality. The
contribution of pulmonary tuberculosis to the aetiology of chronic respiratory disease is rarely
considered, but may be important in tuberculosis-endemic areas.
Methods: We performed a systematic literature review to assess the association between a history of
tuberculosis and the presence of chronic obstructive pulmonary disease (COPD) or chronic suppurative
lung disease (bronchiectasis). Study quality was evaluated using the National Heart Lung and Blood
Institute quality assessment tool. Meta-analysis was performed using the DerSimonian and Laird
random effects model.
Results: We identiﬁed 9 eligible studies for COPD and 2 for bronchiectasis. Overall, there was a
signiﬁcant association between a history of tuberculosis and the presence of COPD in adults aged over
40 years (pooled odds ratio 3.05 (95% conﬁdence interval 2.42, 3.85). Among individual COPD studies the
strongest associations were found in countries with a high incidence of tuberculosis, as well as among
never smokers and younger people.
Conclusion: In tuberculosis endemic areas, tuberculosis is strongly associated with the presence of
chronic respiratory disease in adults. Efforts to improve long-term lung health should be part of
tuberculosis care.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Economic development has been associated with a pronounced
epidemiological transition, resulting in a decreased burden of
infectious diseases, but a greatly increased burden of non-
communicable diseases (NCDs)1. While the epidemiologic transi-
tion is in progress, as it is in many low- and middle-income
countries, people face the double burden of infectious diseases and
non-communicable diseases 2. Bidirectional associations exist
between ‘‘old’ infectious diseases and ‘‘new’’ non-communicable
ones 3. Tuberculosis (TB) is an important case in point.* Corresponding author. Socios En Salud Sucursal, Peru´, Jr. Emeterio Pe´rez,
310 - San Martı´n de Porres, Lima, Peru´ Tel.: +511-612-5200.
E-mail address: abyrne@med.usyd.edu.au (A.L. Byrne).
http://dx.doi.org/10.1016/j.ijid.2014.12.016
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Since M. tuberculosis is spread by aerosol droplets, the lungs are
most commonly affected by the disease 4,5. It is well known that
environmental exposures, such as silica dust or cigarette smoke,
increase the risk of developing TB 6–8. Diabetes, a non-
communicable disease of growing importance, has also been
shown to increase the risk of progression to active TB 9,10.
Conversely, it is now becoming clearer that TB itself may lead
to chronic respiratory disease, particularly bronchiectasis and
COPD 11,12. The population attributable risk for COPD due to
cigarette smoking varies from more than 70% in some high income
countries to less than 40% in low and middle income countries
13. The other factors that cause COPD in low and middle income
countries have not been established, but TB may well play an
important role 14.
Many low and middle-income countries are undergoing
changes that actually increase TB risk, such as rapid urbanization
with high population densities and increased rates of cigaretteciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow diagram demonstrating search strategy used.
COPD excluded studies included 45 studies assessing lung function loss in TB
patients (case series), 28 studies on biomass fuel or smoking, 8 studies the risk of TB
infection with corticosteroid treatment for COPD, 11 studies on silicosis or
pneumoconiosis and 4 studies that looked at the increased risk of lung cancer
following pulmonary tuberculosis infection.
Bronchiectasis excluded studies included 22 on haemoptysis, 10 on non-
tuberculosis mycobacteria, 6 narrative reviews and 25 that described
bronchiectasis in select TB sub-populations.
tw.: Text words used in addition to MeSH;
TB: tuberculosis, mycobacterium tuberculosis, TB, mycobacterial infection, TBC
COPD: chronic respiratory disease, chronic lung disease, chronic obstructive lung
disease, COPD, chronic airway limitation, CAL, lung disorder, asthma, obstructive
lung function, lung function, spirometry, pulmonary function testing.
Bronchiectasis bronchiectasis, chronic suppurative lung disease
MeSH exp.: Medical Subject Heading expanded to include all sub-headings;
Tuberculosis, Respiratory Tract Diseases, Bronchiectasis, Pulmonary Disease,
Chronic Obstructive.
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are current smokers, including 57% of all adult males, and if
these rates do not decrease then the number of smoking-related
deaths in that country will double to an estimated 2 million per
year by 2020 16,17. The poor and socially destitute are particularly
at risk, due to an increased risk of acquiring Mycobacterium
tuberculosis infection in crowded living conditions and a greater
vulnerability to progress to active disease because of co-morbid
conditions 5,18. TB occurred in an estimated 9 million people in
2013 4. This represents a large population at-risk of adverse lung
health outcomes, especially if exposed to additional pulmonary
insults.
Chronic respiratory disease is a group of disorders that
primarily affect the lungs and airways. It is associated with
signiﬁcant morbidity and mortality19. The World Health
Organization (WHO) estimates that 4.6 million people die
prematurely each year as a result of chronic respiratory disease,
accounting for more than 5% of global deaths; almost 90% of
these occur in low and middle-income countries 20. The
2010 global burden of disease report ranked COPD as the 9th
leading cause of disability worldwide and this is predicted to rise
to 5th by 2020 21. In adults COPD is the most common chronic
respiratory disease and bronchiectasis is another debilitating
airway disease that shares some clinical features but is often
under recognised 22,23. It is characterized by persistent airway
dilation and a chronic productive cough 24, leading to repeated
respiratory infections, deterioration in lung function and
reduced quality of life 25,26.
This systematic review examines the available evidence on the
association between TB and chronic respiratory disease, with a
focus on COPD and bronchiectasis. The primary review questions
were,‘‘In the general population is a previous episode of TB
associated with COPD or chronic suppurative lung disease
(bronchiectasis)?’’
2. Methods
We performed a systematic review of the literature in
accordance with PRISMA guidelines 27. The electronic databases
of Medline (Web of Science) and the Cochrane library were
screened for articles that contained the terms 28 ‘‘tuberculosis’’ or
‘‘respiratory tract disease’’. The search then focused speciﬁcally on
‘‘obstructive’’ lung disease or ‘‘bronchiectasis’’ (Figure 1). Studies
relating to reactive airway disease (asthma) and the parenchymal
lung diseases, including pneumoconiosis (silicosis, coal miner’s
pneumoconiosis, and asbestosis) and other causes of pulmonary
ﬁbrosis, were not considered. Articles were limited to human
studies published between January 1975 and September 2014. No
language restrictions were applied. All articles identiﬁed by the
initial search were reviewed by title and abstract for relevance (by
ALB). Duplicates, non-human studies and off-topic articles were
excluded. Narrative reviews, case reports and case series were
also excluded.
Studies that recruited participants from the general population,
including population-based cohort, cross-sectional or nested case-
control studies were included. Full-text of the included studies was
assessed using a standard data collection form, documenting study
setting, study design and participant selection, TB deﬁnition,
COPD/bronchiectasis deﬁnition, key ﬁndings including hazard or
odds ratio, key limitations and follow up period. Two authors (ALB
& CDM) applied the National Heart Lung and Blood Institute
(NHLBI) quality assessment tool for observational cohort and
cross-sectional studies to assess the internal validity and risk of
bias for each study 29. They independently evaluated the
components of the scale as ‘‘Yes’’, ‘‘No’’ ‘‘Not Applicable’’ or ‘‘Not
Recorded’’. This was used to guide the overall rating for the qualityof each study as ‘‘Good’’, ‘‘Fair’’ or ‘‘Poor’’. In case of disagreement a
consensus opinion was reached.
2.1. Meta-analysis
Odds ratios and hazard ratios for TB and chronic respiratory
disease, and their associated standard errors, were log-trans-
formed and then a random effects meta-analysis was performed in
accordance with the method of DerSimonian and Laird 30. This was
implemented in SAS 9.3 (SAS Institute, Cary NC) using the marandom
macro of Senn et al., 31. A forest plot was created using the same
authors’ maforest SAS macro. The combined odds ratio was
estimated as the exponent of the resulting meta-analytic estimate.
Heterogeneity was assessed by Cochrane’s Q and the I2 statistic 32.
Table 1
Characteristics of all studies included in qualitative analysis.
COPD Studies: Design Setting Follow Up Deﬁnition Deﬁnition
Outcome
(Cohort studies) Tuberculosis
Hooper 2012 Cross-sectional BOLD (14 countries) n/a Past TB history ‘‘Modiﬁed’’ GOLD 1
(Fev1/FVC < LLN)
Perez 2012 Cross -sectional PLATINO (Latin America) n/a Past TB history GOLD 2
Lee 2012 Cohort (Nested) Taiwan > 4 years Recorded TB treatment Recorded COPD treatment
Idolor 2011 Cross-sectional Philippines n/a Past TB history GOLD 1
Lee 2011 Cross-sectional Korea n/a Abnormal CXR GOLD 1
(Pre-bronchodilator)
Lamprecht 2011 Cross-sectional BOLD (14 countries) n/a Past TB history GOLD 2
Caballero 2008 Cross-sectional Colombia n/a Past TB history GOLD 2
Menezes 2007 Cross-sectional PLATINO (Latin America) n/a Past TB history GOLD 1
Ehrilich 2005 Cross-sectional South African n/a Past TB history Clinical COPD
Bronchiectasis Studies:
Zhou 2013 Cross-sectional China n/a Past TB history Clinical Bronchiectasis
Kwak 2010 Cross-sectional Korea n/a Past TB history CT Bronchiectasis
n/a: not applicable
GOLD 1: Grade 1 COPD deﬁned by the Global Initiative for Obstructive Lung Disease as a ratio of Forced Expiratory Volume in 1 second (FEV1) to Forced Vital Capacity (FVC) of
less than 70% following the administration of bronchodilator (usually 200-400mcg of inhaled salbutamol).
GOLD 2: Grade 2 COPD deﬁned as an FEV1 of between 50 and 80% of predicted as well as an FEV1/FVC ratio of less than 70% following bronchodilator.
LLN: Lower Limit of Normal (of the predicted ratio rather than the GOLD deﬁnition of 70%).
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Figure 1 presents a ﬂow diagram of the literature search
results. We identiﬁed 39,102 articles using the search terms
‘‘tuberculosis’’ or ‘‘respiratory tract disease’’. The additional
search term ‘‘obstructive’’, identiﬁed 840 articles relevant to
COPD, but only 9 studies fulﬁlled our inclusion criteria by
assessing the prevalence of COPD among the general population
with and without a deﬁned history of previous tuberculosis 33–41.
Two studies that examined data from a sub-group of never-
smokers (deﬁned as less than 20 packets of cigarettes smoked
throughout the subjects entire life or less than 1 cigarette per day
for less than one year) within larger population-based studies
were included in the qualitative analysis, but not in the meta-
analysis 40,41. The meta-analysis only included studies that
assessed ﬁndings in the general population. The search that
focused on ‘‘bronchiectasis’’ identiﬁed 673 articles. Of 75 poten-
tially relevant studies, only 2 assessed whether a previous episode
of TB is associated with the development of bronchiectasis in the
general population (Table 1) 42,43.
3.1. Quality assessment
The 9 studies included in the meta-analysis and the 2 sub-group
analyses of never smokers are summarized in Table 1. None of theTable 2
Simpliﬁed Quality assessment* of all studies included in the qualitative and quantitati
Study Name & Year Hooper
2012
Perez
2012
Lee
2012
Idolor
2011
Lee
2011
Study Type:
C = COPD
B = Bronchiectasis
C C C C C 
Used for Meta-Analysis:
Y= Yes
N=No
Y
N
Y Y Y
Final Quality
Assessment
Good
Fair Fair Fair Fair 
* Quality assessment using the National Heart Lung Blood Institute (NHLBI) quality ass
Rating;
‘‘Good’’ - The lowest risk of bias due to study design
‘‘Fair’’ - Intermediate risk of bias
‘‘Poor’’ - Risk of bias present (may still be appropriate to use in the absence of other dstudies had the primary objective of characterizing the association
between TB and chronic respiratory disease. Nearly all, however,
included self-reported TB or clinical history of TB treatment in
covariate analyses. With the exception of the retrospective cohort
study by Lee 38, all studies were cross-sectional in design.
Consequently, we could not establish the nature of the temporal
relationship between the exposure (TB) and the outcome (COPD/
bronchiectasis).
Of the COPD studies, most were rated as ‘‘Fair’’ or ‘‘Good’’ by
both assessors, representing a low or intermediate risk of bias
(Table 2). One study may have had compromised sensitivity to
detect COPD, due to the absence of post-bronchodilator
spirometry 34. A few studies suffered from potential selection
bias due to low participation rates (<50%), differences between
respondents and non-respondents, poor matching between the
populations assessed for the exposure (TB) and the outcome
(chronic respiratory disease), 34,39 or exclusion of cases diag-
nosed prior to the commencement of the study 38. In spite of
these limitations, the results were still considered valid for
evaluation.
The bronchiectasis studies that were included were consid-
ered to be at a higher risk of bias, due to insufﬁcient information
provided, non-representative sampling methods, different
populations assessed for exposure and outcome, and low
participation rates (<50%) 42,43. However, in the absence ofve (meta-analysis)
Lamprecht
2011
Caballero
2008
Menezes
2007
Ehrilich
2005
Zhou
2013
Kwak
2010
C C C C
B B
N
Y Y Y Y Y
Fair Fair
Good
Fair
Poor Poor
essment tool for Cohort and Cross sectional studies tool. Overall Quality Assessment
ata)
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size for both studies and use of objective computed tomography
imaging for one study), the assessors thought it appropriate
for them to be included in the meta-analysis. Detailed results
using the NHLBI assessment tool are included in the on-line
appendix.
3.2. COPD ﬁndings
Two population-based cross-sectional studies using the
Burden of Obstructive Lung Disease (BOLD) protocol found that
a reported history of TB was associated with spirometry-
conﬁrmed COPD among people aged 40 years and over (odds
ratios (ORs) ranged from 1.78 to 6.31) 33,35. The strongest
association was reported in the Philippines (Table 3) 35. The Latin
American Project for the Investigation of Obstructive Lung
Disease (PLATINO) and the Prevalence of COPD in Colombia
(PREPOCOL) projects also demonstrated strong associations
between a history of TB and the presence of COPD (ORs
2.33 and 2.94 respectively), in the same age group 36,37. Impor-
tantly, the reported odds ratios have been adjusted for known
COPD risk factors, including cigarette smoking and age. In a sub-
analysis of never-smokers over the age of 40 years from the
PLATINO group 40 the OR for COPD among patients with a historyTable 3
Results of Included Studies.
COPD Studies Subjects Age Group Lim
*Hooper 2012 General population
14 different
countries (BOLD)
>40 years - T
su
Perez 2012 Never smokers
(PLATINO)
>40 years Su
(n
*Lee 2012 Taiwanese >18 years - O
se
(su
tre
- N
cig
Taiwanese 18-40 years 
Taiwanese >40 years 
*Idolor 2011 Philippino adults >40 years - T
to
*Lee 2011 Korean adults >18 years - P
CO
- <
Lamprecht 2011 Never smokers
Male (BOLD)
>40 years Su
(n
Never smokers
Female (BOLD)
>40 years 
*Caballero 2008 Colombian adults >40years - T
to
*Menezes 2007 PLATINO >40years - T
to
*Ehrilich 2004 South African Males >15 years - C
of
- P
un
South African Females > 15 years 
Bronchiectasis studies
*Zhou 2013 Chinese adults > 40 years Cl
*Kwak 2010 Korean health
screening
> 18 years - S
(N
- <
* Denotes study used in meta-analysis
OR: Odds ratio
HR: Hazard Ratio
BOLD sites: Adana (Turkey), Cape Town (South Africa), Guangzhou (China), Krakow (Polan
Lexington (USA), Uppsala (Sweden), London (UK), Reykjavik (Iceland), Sydney (Austral
PLATINO sites: Sao Paolo (Brazil), Montevideo (Uruguay), Mexico City (Mexico), Santia
‘‘Never Smokers’’: Have smoked less than 20 packets of cigarettes in their life or less thTB compared to those without was even higher (3.7) than the OR
for the whole population, despite applying a stricter deﬁnition
for COPD 44.
The strength of this effect appears to be strongly correlated
with the national TB incidence rate. Figure 2 displays odds
ratios reported in speciﬁc study settings relative to the WHO
estimated TB incidence rate for that particular country4;
for multi-country studies the mean TB incidence of all
participating countries was used. In countries with a reported
TB incidence of more than 100/100 000 population/year the
odds of having COPD were over three times higher among
people with a history of TB than among people without such a
history (adjusted OR 3.13 for Korean adults; 4.9 and 6.6 for South
African males and females respectively and 6.31 for the
Philippines) 34,35,39.
The effect of TB on COPD appears to be modiﬁed by age. Adults
less than 40 years of age were included in only 3 of 7 COPD
studies,34,38,39 since COPD is relatively uncommon among people
aged less than 40 years. Whilst two of the studies did not report
disaggregated results by age, one study did 38. The Taiwan study
demonstrated that a history of TB was more strongly associated
with COPD in adults younger than 40 years of age (HR 4.29; 95% CI
2.62-7.02) than among adults aged 40 years and over (HR 1.94; 95%
CI1.65-2.2)30,31.itations P-value Odds/Hazard ratio
B exposure
bject to recall bias
0.007 adj. OR: 1.78 (95% CI: 1.17-2.72)
bgroup analysis
ever smokers only)
0.01 adj. OR: 3.7 (95% CI: 1.4-9.6)
utcome subject to
nsitivity bias
bjects on COPD
atment only)
o adjustment for
arette smoking
<0.001 HR: 2.054 (95% CI: 1.768–2.387)
<0.001 HR: 4.291 (95% CI: 2.623–7.020)
<0.001 HR: 1.937 (95% CI: 1.653–2.269)
B exposure subject
 recall bias
<0.0001 adj. OR 6.31 (95% CI: 2.67-15.0)
re-Bronchodilator
PD detection only
 50% Participation
<0.001 adj. OR: 3.13 (95% CI: 1.86-5.29)
bgroup analysis
ever smokers only)
0.464 adj. OR 1.65 (95% CI: 0.43- 6.34)
adj. OR 1.47 (95% CI: 0.69-3.12)
0.323
B exposure subject
 recall bias
0.001 adj. OR: 2.94 (95% CI: 1.58–5.49)
B exposure subject
 recall bias
<0.0001 adj. OR: 2.33 (95% CI: 1.50–3.62
linical diagnosis
 COPD
articipation rate
reported
<0.05 adj. OR: 4.9 (95% CI: 2.6–9.1)
<0.05 adj. OR: 6.6 (95% CI: 3.7–11.7)
inical diagnosis <0.05 adj. OR: 3.07 (95% CI: 1.89-4.98)
election bias possible
ot random simple)
 50% Participation
0.001 adj. OR: 4.61 (95% CI 2.39-8.88)
d), Manila (Philippines), Salzburg (Austria), Hannover (Germany), Bergen (Norway),
ia), Vancouver (Canada).
go (Chile), Caracas (Venezuela).
an 1 cigarette per day for less than one year.
Figure 2. Odds Ratio for COPD in patients with a history of TB, according to the TB incidence in respective study countries.
Study countries included (from highest TB incidence to lowest);
South Africa (Ehrilich 2004), Philippines (Idolor 2011), Republic of Korea (Lee 2011), BOLD countries (Hooper, 2012), Colombia (Caballero, 2008) and PLATINO countries
(Menezes, 2007).
For studies with multiple country sites (BOLD and PLATINO), the average incidence was used as described below.
BOLD*: Average 103 per 100,000/year
Australia (6.5), Austria (7.9), Canada (4.6), China (73), Germany (5.6), Iceland (3.5), Norway (7.5), Philippines (265), Poland (21), United Kingdom (15), United States of
America (3.6), South Africa (1003), Sweden (7.2), Turkey (22).
PLATINO**: Average 29 per 100,000/year
Brasil (46), Chile 16), Mexico (23), Uruguay (27), Venezuela (33).
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The evidence that TB is a risk factor for the subsequent
development of bronchiectasis is less robust than for COPD. Only
2 studies, both from eastern Asia, were included. Study ﬁndings
demonstrated similar and signiﬁcant positive associations. In a
large population-based cross-sectional study of adults aged over
40 years living in urban China (n = 10,811), a history of pulmonary
tuberculosis was signiﬁcantly associated with the medical
diagnosis of bronchiectasis (OR 3.07 with 95% CI 1.89-4.98)
42. Using computed tomography (CT) imaging as the reference
standard, a Korean study also demonstrated a signiﬁcant
relationship between previous TB and bronchiectasis (OR 4.61 with
95% CI 2.39-8.88) among healthy adults aged 23-86 years 43.
3.4. Meta-analysis
Figure 3 shows a forest plot of all the included studies and the
pooled estimate. The pooled effect estimate was 3.05 (95%
conﬁdence interval 2.42 to 3.85; p < 0.0001), but there was
signiﬁcant heterogeneity among studies (Cochrane’s Q 46.2,
P < 0.0001, I2 = 76%). Neither the pooled effect estimate nor the
heterogeneity assessment were signiﬁcantly inﬂuenced by the
inclusion or exclusion of the two bronchiectasis studies.4. Discussion
This systematic review and meta-analysis reveals a strong and
consistent positive association between a history of tuberculosis and
the presence of chronic respiratory diseases (including both COPD
and bronchiectasis). The strength of the association showed
considerable variation depending on the TB incidence rate within
the study setting. The strongest associations between TB and COPD
were reported from countries with higher TB incidence rates, such as
South Africa and the Philippines (OR 6) with estimated annual TB
incidence rates of 1003 and 265 per 100,000 population respectively.
Studies conducted in settings with lower TB incidence rates
(<40/100,000 population) reported lower odds ratios (OR 3).
The multisite BOLD study appears to contradict this observation,
reporting an OR of 1.78 with mean TB incidence of 103/100,000.
However, the mean TB incidence was greatly inﬂuenced by a single
outlier, South Africa, while most of the 14 sites were located in
countries with TB incidence rates below 40/100 000 (except the
Philippines and China).
The association between TB and COPD was found to be stronger
among younger adults (<40yrs), in studies where this was
assessed. This may be explained by the natural history of COPD,
which reﬂects cumulative lung damage that results from
environmental exposures and other lung insults. Cigarette
Figure 3. Effect size of a past history of tuberculosis on COPD or Bronchiectasis.
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destruction and airway obstruction, mediated by both genetic and
behavioural factors (such as the depth of inhalation and pattern of
smoking) 45 is slowly progressive 46, smoking-related COPD is
uncommon in younger people 47. Pulmonary tuberculosis on the
other hand is primarily a disease of young adults 4 and the
associated lung damage occurs during the acute disease process,
which explains why its relative contribution to COPD is higher in
the younger age group, especially in TB endemic areas.
The relationship between TB and COPD in non-smokers is
supported by data from the BOLD and PLATINO studies (high
and middle income countries) 48,49 that performed sub-group
analyses on never-smokers and found even stronger associations
between TB and COPD in people who have never smoked
40,41. Although TB is an established risk factor for obstructive
lung function, the phenotype of ‘‘TB associated COPD’’ is often
considered to be different from ‘‘smoking-related COPD’’
33,36,47. The available evidence suggests that, at least with respect
to some important outcomes, the disease has similar manifesta-
tions, despite different aetiologies. Several studies demonstrate
the persistence of lung function loss, presence of exacerbations as
well as the potential for longer term sequelae and respiratory
failure in patients with ‘‘TB associated COPD’’,50–53 similar to
‘‘smoking-related COPD’’.
The fact that the presence of ventilatory restriction, as
measured by a reduced forced vital capacity (FVC) is an important
predictor of mortality among COPD patients 54 could have
implications for TB patients who have combined restrictive and
obstructive lung function deﬁcits. This is supported by studies
from TB endemic countries such as South Africa, Romania,
Pakistan, India, Korea and Brazil that have characterised the
patterns of lung function loss that exist among pulmonary TB
patients 50,51,55–58. Abnormal lung function, as measured by
spirometry, associated with pulmonary TB was observed in
between 18-94% of patients. The extent of the lung function
abnormality often correlated with the degree of radiological
impairment, number of TB episodes and presence of other
respiratory co-morbidities. There was frequently a combination
of both restriction and obstruction 50–52.
Bronchiectasis has been regarded as an ‘‘orphan’’ lung disease
59. We identiﬁed only 2 studies assessing the association between
TB and bronchiectasis 42,43, although it is known to be common in
patients with extensive TB disease since the time of William Osler
60–62. This may reﬂect the fact that non-invasive tests to conﬁrm
the presence of bronchiectasis (high resolution CT) 63 are relatively
new and rarely available in resource-limited settings, where most
of the world’s TB disease burden is concentrated. Several recent
case series from TB endemic countries support this, with
prevalence of bronchiectasis observed to be as high as 85% among
subjects previously treated for pulmonary TB 64,65. Among patients
presenting with bronchiectasis in Nepal, a past history of TB was
the most common cause of bronchiectasis identiﬁed 66. Multiple
lung insults results in a greater potential for non-reversible lung
injury and not uncommonly a combination of COPD and
bronchiectasis.
Strengths of this meta-analysis include the population-based
focus, the diversity of study settings, the objective outcome
measures used (spirometry or CT in all but 3 studies) and the fact
that outcome assessors were blinded to exposure classiﬁcation.
Nearly all studies adjusted for confounding by risk factors such as
smoking, biomass fuel exposure and low socio-economic status.
Overall methodological quality limited the risk of bias, as judged by
the NHLBI quality assessment process 29. Although there was
signiﬁcant heterogeneity in effect estimates across studies, all
effect estimates for the association between TB and COPD or
bronchiectasis indicated a positive association.Study limitations include cross-sectional assessment, which
precluded an assessment of temporal relationships. Although TB is
likely to contribute to chronic respiratory disease, COPD may be
treated with systemic and inhaled corticosteroids, which are
known to increase the risk of TB 67–70. The retrospective cohort
study by Lee et al (2012) used a nationwide, universal health
insurance database in Taiwan 38. They were able to establish that
no TB patients received COPD treatment in the 3 years prior to their
TB episode. This suggests that COPD treatment did not contribute
to TB vulnerability and the positive association found reﬂects TB as
a contributing factor to COPD development. Few studies assessed
the presence of post-bronchodilator airﬂow obstruction in people
aged less than 40 years, which limits the generalizability of our
ﬁndings concerning the modiﬁcation of the effect by age. Although
we have combined both odds ratios and hazard ratios in this meta-
analysis, we believe this is unlikely to result in any important bias
in the estimation of the pooled estimates. Our review did not ﬁnd
any population based studies from low income countries, where TB
is likely to be a signiﬁcant contributor to chronic lung disease.
The ﬁndings are important for public health practitioners and
policy makers, because of the strength and consistency of the
association and the magnitude of the problem. With COPD now the
3rd most common cause of death globally 21, there is an urgent
need to prevent the signiﬁcant number of non-smoking (and
smoking) related COPD cases, particularly in TB endemic areas.
Reduction in cigarette smoking is essential to reduce the
prevalence of COPD in high, middle and low income countries
54. However, in low income countries up to a third of COPD patients
have never smoked 71. Tuberculosis, on the other hand, is common
with 80% of the 9 million new cases this year occurring in low and
middle income countries 4,72.
5. Conclusion
The respiratory effects of smoking and its impact on COPD are
well known. However, the lung sequelae of pulmonary TB may be a
signiﬁcant contributor to COPD population attributable risk,
particularly in TB endemic areas and in younger adults. In addition,
increasing rates of cigarette smoking, together with worsening air
pollution (indoor and outdoor) will exacerbate the lung damage
that results from TB. It demonstrates the need to improve TB
control and to link patients to ongoing care after TB treatment
completion, but also for comprehensive strategies to improve lung
health at the population level.
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